Clinical features and disease management in adult patients with atopic dermatitis receiving care at reference hospitals in brazil: The adapt study

Arruda L.K.; Yang A.C.; Aoki V.; Criado R.F.J.; Pires M.C.; Lupi O.; Fabricio L.H.Z.; Richman D.; Silvi S.

Clinical features and disease management in adult patients with atopic dermatitis receiving care at reference hospitals in brazil: The adapt study

Tipo

Artigo

Data de publicação

2021

Periódico

Journal of Investigational Allergology and Clinical Immunology

Citações (Scopus)

7

Autores

Arruda L.K.
Yang A.C.
Aoki V.
Criado R.F.J.
Pires M.C.
Lupi O.
Fabricio L.H.Z.
Richman D.
Silvi S.

Resumo

© 2021 Esmon Publicidad.Background: Atopic dermatitis is a chronic inflammatory skin disease with a prevalence of 0.02% to 8.1% in adults. Adult patients with moderate-to-severe atopic dermatitis are affected by frequent relapses and a significant disease burden. Objective: To determine the clinical, immunological, and therapeutic profile of Brazilian adults with atopic dermatitis. Methods: A multicenter, observational, retrospective, descriptive registry-based study was conducted at reference hospitals between December 2016 and October 2017. The data collected were demographics, personal and family history of atopic diseases, clinical manifestations, laboratory tests, disease severity and management. Results: Of the 187 patients included in the analysis, 56.1% were female and 71.7% were White, with a mean age of 24.7 years. Mean follow-up was 9 years. Asthma or other allergic diseases were reported by 80.2% of patients. The main comorbidity was hypertension (10.2%), and common disease manifestations included pruritus and erythema. Lesions generally affected flexural and nonflexural areas, with typical morphology. Around 83% of patients had moderate-to-severe disease, and 8.6% reported at least 1 hospitalization. Most patients received topical and/or systemic pharmacological therapies, including omalizumab (5.9%); 4.3% received phototherapy. Moreover, 66.8% of patients received adjuvant therapy, and 79.1% changed or discontinued treatment for atopic dermatitis due to remission (46.5%), poor effectiveness (33.7%), or lack of adherence (12.9%). Most patients presented characteristics of type 2 inflammation, with immunoglobulin E levels above 100 IU/mL (94.4%) and peripheral blood eosinophils above 5% (55.9%). Conclusion: Brazilian adult patients with severe atopic dermatitis need treatment to efficiently control the disease and improve quality of life.

Assuntos Scopus

Adult , Brazil , Comorbidity , Demography , Dermatitis, Atopic , Disease Progression , Eosinophils , Erythema , Female , Follow-Up Studies , Hospitalization , Humans , Hypertension , Immunoglobulin E , Male , Omalizumab , Pruritus , Tertiary Care Centers